Belgium’s Ogeda to be bought by Astellas

The privately-owned Belgian drug developer Ogeda SA is to be acquired by Astellas Pharma Inc of Japan in a deal potentially valued at €800 million. Ogeda is developing products for women’s health that target G-protein coupled receptors (GPCRs).

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Belgium